Cariprazine (Vraylar) is primarily approved for the treatment of which disorder?

Cariprazine (Vraylar) is primarily approved for the treatment of schizophrenia, making it the correct choice. This medication is classified as an atypical antipsychotic and works by modulating neurotransmitters in the brain, particularly dopamine and serotonin, which are involved in regulating mood, cognition, and perception.

While cariprazine has also been studied for its efficacy in treating other conditions, such as bipolar disorder and depression (notably as an adjunctive treatment), its primary indication remains for schizophrenia. This aligns with the understanding that it is effective in managing symptoms associated with this severe mental health disorder, which can include delusions, hallucinations, and disorganized thinking.

The other disorders listed, such as borderline personality disorder, major depressive disorder, and obsessive-compulsive disorder, do not have cariprazine as a primary treatment option. It’s important for practitioners to align pharmacological treatments with the documented indications to ensure effective management of patients’ conditions.